Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.

British journal of cancer - 20 Aug 2007

Cheng I, Liu X, Plummer S J, Krumroy L M, Casey G, Witte J S

Abstract excerpt

Collective evidence suggests that cyclooxygenase 2 (COX2) plays a role in prostate cancer risk. Cyclooxygenase 2 is the major enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of COX2 and long-term use of NSAIDs appears to modestly lower the risk of prostate cancer. We investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Case-Control Studies
Share to Cyclooxygenase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Haplotypes

Share to Linkage Disequilibrium

Share to Prostatic Neoplasms

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 17609663
DOI: 10.1038/sj.bjc.6603874
PMCID: PMC2360347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.PMID 17609663Read ↗

Genetic variation in the COX-2 gene and the association with prostate cancer risk.Semantic proximity Read ↗

Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men.Semantic proximity Read ↗

COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men.Semantic proximity Read ↗

Pharmacogenomics of cyclooxygenases.Semantic proximity Read ↗

Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort.Semantic proximity Read ↗

Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.Semantic proximity Read ↗

Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement.Semantic proximity Read ↗

Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis.Semantic proximity Read ↗

Lack of association between the cyclooxygenase 2 -765G>C polymorphism and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk.Semantic proximity Read ↗

COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.Semantic proximity Read ↗

Toll-like receptor 4 genetic variation and advanced prostate cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.